Abiopharma

🔍 Gonnella Michael (Executive)

Company: PERSHING SQUARE INC. (PS)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Sold 192,426 shares of Common Stock (Direct)
  Date: 2026-04-30 | Code: D | equity_swap_involved: 0 | shares_owned_after: 2,606,804.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 20,000 shares of Common Stock (Direct)
  Date: 2026-04-30 | Code: J | equity_swap_involved: 0 | shares_owned_after: 2,626,804.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 5,213,610 shares of M Units of Pershing Square Partner Group, LLC (Derivative)
  Date: 2026-04-28 | Code: A | equity_swap_involved: 0 | shares_owned_after: 5,598,461.00 | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4

Footnotes:

• F1: On April 30, 2026, the Issuer and Pershing Square USA, Ltd. ("PSUS") completed a combined transaction, consisting of (i) an initial public offering (the "PS IPO") and a concurrent private placement of Issuer common stock and (ii) an initial public offering (the "PSUS IPO" and together with the PS IPO, the "combined IPO") and a concurrent private placement of PSUS's Common Shares of Beneficial Interest ("PSUS Common Shares") (collectively, the "combined transaction").
• F2: Pursuant to the Amended and Restated Purchase Price Adjustment Agreement (the "A&R Purchase Price Adjustment Agreement") by and among the Issuer, Pershing Square Partner Group, LLC ("PSPG") and the other parties thereto (including the Reporting Person), PSPG and other parties thereto (including the Reporting Person) contributed Issuer common stock to the Issuer in an aggregate amount equal to the number of shares of Issuer common stock issued in connection with the combined transaction. Each party's contribution ("Purchase Price Adjustment Contribution") corresponds to such party's pro rata share of the aggregate number of shares of Issuer common stock held by the parties as of immediately prior to the completion of the combined transaction.
• F3: Reflects the acquisition of Issuer common stock in connection with the combined IPO. In connection with the PS IPO, each initial investor acquired 1 share of Issuer common stock for no additional consideration for every 5 PSUS Common Shares that the investor purchased in the PSUS IPO.
• F4: These M Units ("M Units") of PSPG were granted to the Reporting Person pursuant to an amendment of PSPG's governing document on a pro rata basis of the Reporting Person's prior interest in PSPG on April 28, 2026. The M Units are unvested and subject to vesting and forfeiture. The standard vesting schedule for M Units provides for vesting (i) 6.25% each year during years 1 to 4, (ii) 8.33% each year during years 5 to 7, and (iii) 16.67% each year during years 8 to 10. The grant was approved by the board of directors of the Issuer in accordance with Rule 16b-3 under the Securities Exchange Act of 1934, as amended.
• F5: Upon vesting, each M Unit may be redeemed by the holder, subject to certain conditions, for shares of Issuer common stock held by PSPG on a one-for-one basis, subject to certain adjustments pursuant to the terms approved by the board of directors of the Issuer. These redemption rights do not expire.
• F6: Reflects the pro rata adjustment, pursuant to PSPG's governing document in connection with its Purchase Price Adjustment Contribution, of the number of shares of Issuer common stock for which each M unit may be redeemed.